International: +1-347-960-6455
Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years

According to a new research report Immunoglobulin A (IgA) Nephropathy-Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2028” published by Pharma Proff, Immunoglobulin A (IgA) Nephropathy therapeutics currently exhibits a proliferating pipeline with 24 therapeutic candidates.

Insights into IgA Nephropathy Pipeline

IgA Nephropathy is referred to being as the utmost causing agent of Glomerulonephritis, which is the inflammation of the glomeruli (part of the kidney that filters blood). IgA antibodies are produced by immune system and act as first line of defense against inhaled and ingested pathogens. IgA Nephropathy is an auto immune disorder caused due to the accumulation of the immunoglobulin A (IgA) which results in inflammation and further damages the glomeruli in kidney. This damage to kidney results in presence of blood and protein in urine, and over time may progress to end-stage renal disease (ESRD).

Researchers have found that, the disease is majorly being observed in the male population as compared to the female population and is specifically prevalent in Asian or Caucasian population. Further, genetic factors also play a key role as a cause of the disease. Researchers believe, that even after a lack of specific treatment for IgA Nephropathy, the process of kidney damage can be slowed down by the use of fish oil supplements, immunosuppressive drugs, corticosteroids angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors.

Insights into Pipeline Segments

According to research findings, majority of the drug candidates in IgA Nephropathy pipeline are undergoing Phase II trials and have shown positive results. It has been observed that subcutaneous route of administration is convenient because of more efficacy and safety; it is more adoptable because of its larger dosage, that can be transmitted subcutaneously; sustainable release of drugs is possible as the muscles can slowly release the drugs into the body. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.

Insights into Epidemiology Analysis

The epidemiology analysis in the report provides risk factors and trends of IgA Nephropathy in seven major markets (7MM, including U.S., Japan, and EU5 [which includes Germany, France, U.K., Italy, and Spain]) and gives a ten-year forecast for the prevalent and treated cases of IgA nephropathy in each of the regions in pediatric, adult, and geriatric populations. Europe is likely to have the highest number of prevalent cases of IgA Nephropathy among the 7MM throughout the period of analysis.

Positive Clinical Trial Results are Expected to Drive the Advancements in IgA Nephropathy Pipeline

The companies developing the drugs for the treatment of IgA Nephropathy, have shown positive clinical results in the various phases of drug development. For instance, in March 2015, Mallinckrodt plc presented two separate presentations in the U.S. in 2015 Spring Clinical Meetings of the National Kidney Foundation (NKF) and announced the positive results of ACTH (Acthar) Gel, which showed well tolerability and a clinically meaningful response.

Browse Detailed Report on "Immunoglobulin A (IgA) Nephropathy - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2028" at:

Technological Advancements Play a Pivotal Role in the IgA Nephropathy Pipeline Development

It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of IgA Nephropathy drugs. These technologies play an important role in the drug development thereby helping the companies develop more specific and effective targeted therapies.

For instance, Calliditas Therapeutics AB is using TARGIT drug delivery technology platform for developing its drug candidate for treating IgA Nephropathy. Calliditas Therapeutics AB, which was formerly known as Pharmalink AB, is engaged in the development of specialty pharmaceutical products for patients with unmet medical needs. The company is focused on the development and commercialization of Nefecon for patients suffering with IgA Nephropathy. Rigel Pharmaceuticals Inc. is developing its drug candidate Fostamatinib using TARGIT drug delivery technology platform, that enables the localized delivery of the drugs to the lower small intestine or colonic regions of the gut.

Some of the key players involved in the development of the drug candidates for IgA Nephropathy in the late and mid stage include Mallinckrodt plc, Calliditas Therapeutics AB., Anthera Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Merck KGaA, Retrophin Inc., and Omeros Corporation.

IgA Nephropathy Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises of detailed pipeline analysis of IgA Nephropathy, analyzing the emerging therapies and their progress status in different phases of development. Comprehensive insights into the pipeline phase products has been provided with special focus on strategic development activities inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, and patent. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to IgA Nephropathy. It also provides epidemiology analysis of the disease in 7MM.